一项包含 22 项研究、1721 名 HCC 患者的荟萃分析表明,PET/CT 可能有助于预测预后【ay be useful for predicting prognosis 】(即 OS 和 DFS,P < .001), 但它与 HCC 检测的敏感性【sensitivity】低相关。 【4】多项荟萃分析表明...
[10] NCCN指南:肝细胞癌(2023 V1). [11] Reig M, BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. [12] Singal AG, et al. Hepatology. 2023 May 22. [13] 《CSCO...
[1]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin.2021;71(3):209–249. [2]Reig M,Forner A,Ri...
Z, Mcgrath N A, et al. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2021, 11: 650292.[10] Shimose S, Iwamoto H, Tanaka M, et al. Association between Adverse Events and Prognosis ...
[10] Shimose S, Iwamoto H, Tanaka M, et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study[J]. Cancers (Basel), 2022, 14(17). [11] Xu J, Shen J, Gu S, et al. Camr...
[10] Shimose S, Iwamoto H, Tanaka M, et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study[J]. Cancers (Basel), 2022, 14...
2024 年 5 月,该研究团队在 Clinical and Translational Medicine 杂志上发表了题为 Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study 的论文。论文详细介绍了这种用于 HCC 早期筛查和预后评估的监测工具的构建过程和检测效果。研究...
1. Scheiner B , Pomej K , Kirstein M M , et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score[J]. 2022. 2. Yang Y, Ouyang J, Z...
[10] Shimose S, Iwamoto H, Tanaka M, et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study[J]. Cancers (Basel), 2022, 14(...
[10] Shimose S, Iwamoto H, Tanaka M, et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study[J]. Cancers (Basel), 2022, 14(17). ...